CLDI
Income statement / Annual
Last year (2023), Calidi Biotherapeutics, Inc.'s total revenue was $0.00,
a decrease of 100.00% from the previous year.
In 2023, Calidi Biotherapeutics, Inc.'s net income was -$29.22 M.
See Calidi Biotherapeutics, Inc.’s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
| Period Ended |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
| Operating Revenue |
$0.00
|
$45,000.00
|
$449,000.00
|
$0.00
|
| Cost of Revenue |
$1.26 M |
$274,000.00 |
$94,000.00 |
$0.00 |
| Gross Profit |
-$1.26 M |
-$229,000.00 |
$355,000.00 |
$0.00 |
| Gross Profit Ratio |
0 |
-5.09 |
0.79 |
0 |
| Research and Development
Expenses |
$13.01 M
|
$7.26 M
|
$4.67 M
|
$3.18 M
|
| General & Administrative
Expenses |
$15.98 M
|
$15.90 M
|
$6.16 M
|
$3.59 M
|
| Selling & Marketing
Expenses |
$0.00
|
-$260,000.00
|
-$4.38 M
|
$0.00
|
| Selling, General &
Administrative Expenses |
$15.98 M
|
$15.64 M
|
$1.78 M
|
$3.59 M
|
| Other Expenses |
$0.00 |
-$5,000.00 |
$9,000.00 |
$4,000.00 |
| Operating Expenses |
$28.99 M |
$22.90 M |
$1.78 M |
$6.77 M |
| Cost And Expenses |
$28.99 M |
$23.17 M |
$1.78 M |
$6.77 M |
| Interest Income |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Interest Expense |
$1.07 M |
$158,000.00 |
$614,000.00 |
$163,000.00 |
| Depreciation &
Amortization |
$1.26 M
|
$260,000.00
|
$153,000.00
|
$117,000.00
|
| EBITDA |
-$28.60 M
|
-$25.00 M
|
-$9.45 M
|
-$6.65 M
|
| EBITDA Ratio |
0 |
-508.18 |
-3.97 |
0 |
| Operating Income Ratio
|
0
|
-513.96
|
-3.97
|
0
|
| Total Other
Income/Expenses Net |
-$208,000.00
|
-$2.29 M
|
-$440,000.00
|
-$1.16 M
|
| Income Before Tax |
-$29.20 M |
-$25.42 M |
$3.39 M |
-$7.93 M |
| Income Before Tax Ratio
|
0
|
-564.8
|
7.54
|
0
|
| Income Tax Expense |
$16,000.00 |
$11,000.00 |
$11,000.00 |
$4,000.00 |
| Net Income |
-$29.22 M |
-$25.43 M |
$3.39 M |
-$7.94 M |
| Net Income Ratio |
0 |
-565.04 |
7.54 |
0 |
| EPS |
-1.73 |
-29.9 |
1.18 |
-0.22 |
| EPS Diluted |
-17.3 |
-29.9 |
1.18 |
-0.22 |
| Weighted Average Shares
Out |
$16.89 M
|
$850,500.00
|
$2.88 M
|
$35.91 M
|
| Weighted Average Shares
Out Diluted |
$1.69 M
|
$850,500.00
|
$2.88 M
|
$35.91 M
|
| Link |
|
|
|
|
